INT50948

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 8
Disease Relevance 4.55
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (SLC12A2) plasma membrane (SLC12A2) transmembrane transport (SLC12A2)
Anatomy Link Frequency
arm 2
dendrites 1
blood 1
SLC12A2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Glutamate receptor 2 87.88 High High
potassium channel 14 71.60 Quite High
abdominal pain 4 65.88 Quite High
pruritus 11 60.64 Quite High
Morphine 2 50.00 Quite Low
cytokine 1 50.00 Quite Low
palliative 4 5.00 Very Low Very Low Very Low
Antihistamine 4 5.00 Very Low Very Low Very Low
methotrexate 3 5.00 Very Low Very Low Very Low
tetrodotoxin 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 159 100.00 Very High Very High Very High
Leukemia 8 99.98 Very High Very High Very High
Disease 123 96.72 Very High Very High Very High
Hypersensitivity 15 92.92 High High
Ganglion Cysts 3 91.20 High High
Hypomagnesemia 21 90.80 High High
Diarrhoea 20 89.68 High High
Toxicity 60 88.96 High High
Myeloid Leukemia 24 86.68 High High
Disease Progression 23 82.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus KCC2 is expressed wherever the chloride equilibrium potential ECl<Erest (resting potential), whereas NKCC1 is expressed wherever ECl>Erest (ON bipolar dendrites).
Gene_expression (expressed) of NKCC1 in dendrites
1) Confidence 0.59 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2481396 Disease Relevance 0.20 Pain Relevance 0.12
Peripheral blood mononuclear cells were tested for acute and gamma-interferon-stimulated natural killer cell cytotoxicity (NKCC), antibody-dependent cell cytotoxicity, antibody Fc receptor expression, and human immunodeficiency virus infectivity.
Gene_expression (expression) of NKCC in blood
2) Confidence 0.19 Published 1995 Journal Anesthesiology Section Body Doc Link 7661350 Disease Relevance 0 Pain Relevance 0
Subgroup analysis, based on the original potential preselected conventional care arm, revealed a significant improvement in time to leukemia progression in the azacitidine vs BSC arm (15 months vs 10.1 months).
Gene_expression (azacitidine) of BSC in arm associated with leukemia
3) Confidence 0.18 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939768 Disease Relevance 0.45 Pain Relevance 0
Subgroup analysis, based on the original potential preselected conventional care arm, revealed a significant improvement in time to leukemia progression in the azacitidine vs BSC arm (15 months vs 10.1 months).
Gene_expression (progression) of BSC in arm associated with leukemia
4) Confidence 0.18 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939768 Disease Relevance 0.45 Pain Relevance 0
Cetuximab produced a significantly higher objective response rate than BSC alone (6.6% vs 0%; p < 0.0001), and also allowed more patients to achieve stable disease (29.6% vs 10.2%).
Gene_expression (produced) of BSC associated with disease
5) Confidence 0.13 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721306 Disease Relevance 0.24 Pain Relevance 0
Most had ECOG score of 0–1 (87% panitumumab, 84% BSC); 42% of panitumumab patients and 39% of the BSC group were aged ?
Gene_expression (group) of BSC
6) Confidence 0.12 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012427 Disease Relevance 0.99 Pain Relevance 0.10
A large, phase III, multicenter, pivotal trial (study 408) has randomized patients with oxaliplatin and irinotecan-refractory EGFR-expressing metastatic colorectal cancer between best supportive care (BSC) and BSC plus panitumumab at a dose of 6 mg/m2 every 2 weeks (Van Cutsem et al. 2007).
Gene_expression (expressing) of BSC associated with colon cancer
7) Confidence 0.12 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012427 Disease Relevance 1.10 Pain Relevance 0
A large, phase III, multicenter, pivotal trial (study 408) has randomized patients with oxaliplatin and irinotecan-refractory EGFR-expressing metastatic colorectal cancer between best supportive care (BSC) and BSC plus panitumumab at a dose of 6 mg/m2 every 2 weeks (Van Cutsem et al. 2007).
Gene_expression (expressing) of BSC associated with colon cancer
8) Confidence 0.12 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012427 Disease Relevance 1.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox